- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04198766
Estudo de INBRX-106 e INBRX-106 em Combinação com Pembrolizumabe em Indivíduos com Tumores Sólidos Localmente Avançados ou Metastáticos (Agonista OX40 Hexavalente)
Um estudo aberto, multicêntrico, primeiro em humanos, escalonamento de dose, fase 1 de INBRX-106 e INBRX-106 em combinação com pembrolizumabe em indivíduos com tumores sólidos localmente avançados ou metastáticos
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Medicamento: INBRX-106 - Hexavalent OX40 agonist antibody
- Medicamento: pembrolizumab 200 mg
- Medicamento: pembrolizumab 400 mg
- Medicamento: Carboplatin AUC-5
- Medicamento: Pemetrexed 500 mg/m2
- Medicamento: Cisplatin 75mg/m2
- Medicamento: Carboplatin AUC-6
- Medicamento: Paclitaxel 200mg/m2
- Medicamento: Nab paclitaxel 100mg/m2
- Medicamento: Gemcitabine (1000 mg/m2)
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Study Director - Inhibrx Biosciences, Inc
- Número de telefone: 858-500-7833
- E-mail: clinicaltrials@inhibrx.com
Locais de estudo
-
-
-
Singapore, Cingapura
- Concluído
- Curie Oncology
-
Singapore, Cingapura
- Concluído
- Icon Cancer Centre Farrer Park
-
Singapore, Cingapura
- Concluído
- Icon Cancer Centre Mount Alvernia
-
-
-
-
-
Busan, Coréia do Sul
- Ainda não está recrutando
- Inje University College of Medicine
-
Investigador principal:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si, Coréia do Sul
- Ainda não está recrutando
- Chungbuk National University Hospital
-
Investigador principal:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do, Coréia do Sul
- Recrutamento
- The Catholic University of Korea, St. Vincent's Hospital
-
Investigador principal:
- Byoung Yong Shim
-
Hwasun, Coréia do Sul
- Ainda não está recrutando
- Chonnam National University Hwasun Hospital
-
Investigador principal:
- In-Jae Oh, MD, MS, PhD
-
Incheon, Coréia do Sul
- Ainda não está recrutando
- Gachon University Gil Medical Center
-
Investigador principal:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si, Coréia do Sul
- Ainda não está recrutando
- CHA Bundang Medical Center
-
Investigador principal:
- Yoon Beom Sang
-
Seoul, Coréia do Sul
- Recrutamento
- Asan Medical Center
-
Contato:
- Bokyeong Jung, RN
- E-mail: bokyeong_jung@amc.seoul.kr
-
Investigador principal:
- Dae Ho Lee, MD
-
Seoul, Coréia do Sul
- Recrutamento
- Severance Hospital, Yonsei University Health System
-
Contato:
- Miyeon Lee
- E-mail: lee_my@yuhs.ac
-
Investigador principal:
- Sun Mun Lim
-
Seoul, Coréia do Sul
- Recrutamento
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
Investigador principal:
- SookHee Hong
-
Contato:
- Na Ayn
- E-mail: Ahnna331@gmail.com
-
Seoul, Coréia do Sul
- Ainda não está recrutando
- Korea University Anam Hospital
-
Investigador principal:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul, Coréia do Sul
- Ainda não está recrutando
- Hanyang University Seoul Hospital
-
Investigador principal:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul, Coréia do Sul
- Ainda não está recrutando
- Korea University Guro Hospital
-
Investigador principal:
- Sung Yong Lee
-
Investigador principal:
- Sung Yong Lee, MD, MS, PhD
-
Suwon, Coréia do Sul
- Ainda não está recrutando
- Ajou University Hospital
-
Investigador principal:
- Yong-Won Choi, MD
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Ativo, não recrutando
- City of Hope
-
Glendale, California, Estados Unidos, 91204
- Recrutamento
- Oncura Health
-
Contato:
- Elizabeth Brown
- E-mail: Elizabeth.Brown@lahomg.com
-
Investigador principal:
- Sungwon Kyung, MD
-
La Jolla, California, Estados Unidos, 92037
- Ainda não está recrutando
- UC San Diego Health - Moores Cancer Center
-
Investigador principal:
- Lyudmila Bazhenova, MD
-
Los Angeles, California, Estados Unidos, 90027
- Recrutamento
- California Research Institute
-
Investigador principal:
- Ghassan Al-Jazayrly, MD
-
Contato:
- Swati Shrestha
- E-mail: sw@caresinst.com
-
Los Angeles, California, Estados Unidos, 90069
- Recrutamento
- Valkyrie Clinical Trials
-
Investigador principal:
- David Berz, MD
-
Contato:
- Myo Zaw
- E-mail: myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles, California, Estados Unidos, 90033
- Ainda não está recrutando
- University of Southern California Norris Comprehensive Cancer Center
-
Investigador principal:
- Jorge Nieva, MD
-
Murrieta, California, Estados Unidos, 92562
- Recrutamento
- Valkyrie Clinical Trials
-
Investigador principal:
- David Berz, MD
-
Contato:
- Isabella Gudino
- E-mail: Isabella.gudino@vctcare.com
-
Santa Rosa, California, Estados Unidos, 95403
- Recrutamento
- Providence Medical Foundation
-
Investigador principal:
- Ian Anderson, MD
-
Contato:
- Clinical Research Coordinator
- Número de telefone: 1181 707-521-3810
- E-mail: jackson.barnard@providence.org
-
-
Colorado
-
Lakewood, Colorado, Estados Unidos, 80228
- Ainda não está recrutando
- Valkyrie Clinical Trials - Colorado
-
Investigador principal:
- Jason Henry, MD
-
-
Florida
-
Clermont, Florida, Estados Unidos, 34711
- Recrutamento
- Clermont Oncology Center
-
Investigador principal:
- Gopal Kunta, MD
-
Contato:
- Kiran Penta
- E-mail: kiran@aorcorp.com
-
Orange City, Florida, Estados Unidos, 32763
- Recrutamento
- Mid Florida Hematology and Oncology Center
-
Investigador principal:
- Santosh Nair, MD
-
Contato:
- Kiran Penta
- E-mail: kiran@aorcorp.com
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Ativo, não recrutando
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Ainda não está recrutando
- University of Illinois Cancer Center
-
Investigador principal:
- Frank Weinberg, MD, PhD
-
Chicago, Illinois, Estados Unidos, 60637
- Ativo, não recrutando
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa
-
Investigador principal:
- Douglas Laux, MD
-
Contato:
- Jordan Harrelson
- Número de telefone: 319-467-5831
- E-mail: Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Recrutamento
- Norton Cancer Institute
-
Investigador principal:
- John Hamm, MD
-
Contato:
- Jenn Broadway, RN
- Número de telefone: 19535 502-629-2500
- E-mail: Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Recrutamento
- Henry Ford Cancer Institute
-
Investigador principal:
- Amy Weise, MD
-
Contato:
- Mahmoud Hossami
- Número de telefone: 313-725-7842
- E-mail: mhossam1@hfhs.org
-
Detroit, Michigan, Estados Unidos, 48201
- Concluído
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids, Michigan, Estados Unidos, 49546
- Ativo, não recrutando
- START Midwest
-
-
Minnesota
-
Saint Louis Park, Minnesota, Estados Unidos, 55426
- Ativo, não recrutando
- HealthPartners Cancer Research Center
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Concluído
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Ainda não está recrutando
- Washington University in St. Louis School of Medicine
-
Investigador principal:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings, Montana, Estados Unidos, 59102
- Concluído
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island, Nebraska, Estados Unidos, 68803
- Ainda não está recrutando
- Nebraska Cancer Specialists - Grand Island
-
Investigador principal:
- Ralph Hauke, MD
-
Omaha, Nebraska, Estados Unidos, 68130
- Recrutamento
- Nebraska Cancer Specialists
-
Investigador principal:
- Ralph Hauke, MD
-
Contato:
- Lindsey Becker
- Número de telefone: 402-691-5255
- E-mail: lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Ainda não está recrutando
- MD Anderson Cancer Center at Cooper
-
Investigador principal:
- Polina Khrizman, MD
-
-
New York
-
The Bronx, New York, Estados Unidos, 10467
- Ativo, não recrutando
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Ativo, não recrutando
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97213
- Ativo, não recrutando
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Ainda não está recrutando
- Lehigh Valley Health Network
-
Investigador principal:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37923
- Ainda não está recrutando
- University of Tennessee Health Science Center
-
Investigador principal:
- Sean Jordan, MD
-
Nashville, Tennessee, Estados Unidos, 37204
- Ativo, não recrutando
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75230
- Concluído
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso, Texas, Estados Unidos, 79915
- Concluído
- Renovatio Clinical - El Paso
-
San Antonio, Texas, Estados Unidos, 78229
- Concluído
- NEXT Oncology
-
The Woodlands, Texas, Estados Unidos, 77380
- Concluído
- Renovatio Clinical
-
Tyler, Texas, Estados Unidos, 75701
- Recrutamento
- The University of Texas Health Science Center at Tyler
-
Contato:
- Chaney Story
- E-mail: Chaney.Story@uttyler.edu
-
Investigador principal:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Concluído
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Froedtert Hospital and the Medical College of Wisconsin
-
Investigador principal:
- Jonathan Thompson, MD
-
Contato:
- Ellen Smith
- E-mail: eksmith@mcw.edu
-
-
-
-
-
Changhua, Taiwan
- Ativo, não recrutando
- Changhua Christian Hospital (CCH)
-
Kaohsiung City, Taiwan
- Ativo, não recrutando
- E-Da Cancer Hospital
-
Kaohsiung City, Taiwan
- Ativo, não recrutando
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan, Taiwan
- Ativo, não recrutando
- National Cheng Kung University Hospital
-
Taipei, Taiwan
- Concluído
- Taipei Veterans General Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimental: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
|
|
Experimental: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
|
|
Experimental: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
|
|
Experimental: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Outros nomes:
|
|
Experimental: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Outros nomes:
|
|
Comparador Ativo: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimental: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Experimental: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
|
|
Experimental: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
|
|
Experimental: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Outros nomes:
|
|
Experimental: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Outros nomes:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
Experimental: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
Experimental: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
|
|
Experimental: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Outros nomes:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Outros nomes:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Prazo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Prazo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Prazo: ~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Prazo: ~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Prazo: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Prazo: ~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
Prazo: ~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
Prazo: ~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
Prazo: ~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
Prazo: ~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
Prazo: ~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Prazo: ~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Prazo: ~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Diretor de estudo: Clinical Lead, Inhibrx Biosciences, Inc
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- Câncer de Cabeça e Pescoço
- Câncer de pulmão
- NSCLC
- Câncer de Pulmão de Células Não Pequenas
- Carcinoma
- Neoplasias
- Imunoterapia
- Pembrolizumabe
- Quimioterapia
- Keytruda
- HNSCC
- Neoadjuvante
- Agentes Antineoplásicos
- Adjuvante
- Tumores Sólidos
- Câncer bucal
- Câncer de orofaringe
- INBRX-106
- Agentes Antineoplásicos Imunológicos
- Neoplasias de Cabeça e Pescoço
- Neoplasias Glandulares e Epiteliais
- Neoplasias por Tipo Histológico
- Neoplasias por local
- Carcinoma Espinocelular de Cabeça e Pescoço
- Mecanismos Moleculares de Ação Farmacológica
- PD-L1 positivo
- Neoplasias de Células Escamosas
- Carcinoma de Células Escamosas
- Câncer de hipofaringe
- Fase 1 e Fase 2
- Ensaio Clínico de Fase 1 e Fase 2
- Agonista do receptor OX40
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças bucais
- Doenças estomatognáticas
- Neoplasias urogenitais
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças Respiratórias
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Doenças do Estômago
- Doenças pulmonares
- Adenocarcinoma
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Doenças de pele
- Neoplasias Urológicas
- Doenças Otorrinolaringológicas
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Neoplasias Renais
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Tumores Neuroendócrinos
- Neoplasias faríngeas
- Neoplasias Otorrinolaringológicas
- Doenças Faríngeas
- Nevos e Melanomas
- Neoplasias Cutâneas
- Doenças da Pele e do Tecido Conjuntivo
- Carcinoma Espinocelular de Cabeça e Pescoço
- Neoplasias
- Neoplasias do Estômago
- Carcinoma
- Neoplasias Pulmonares
- Carcinoma de Células Escamosas
- Carcinoma de Células Renais
- Carcinoma pulmonar de células não pequenas
- Neoplasias de Cabeça e Pescoço
- Melanoma
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Neoplasias de Células Escamosas
- Neoplasias Bucais
- Carcinoma de Células de Transição
- Neoplasias Orofaríngeas
- Neoplasias por local
- Neoplasias Hipofaríngeas
- Aminoácidos, peptídeos e proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Hidrocarbonetos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Terpenos
- Produtos químicos inorgânicos
- Compostos de cloro
- Compostos de nitrogênio
- Guanina
- Hipoxantinas
- Purinonas
- Purinas
- Glutamatos
- Aminoácidos, ácido
- Aminoácidos
- Aminoácidos, dicarboxílico
- Taxóides
- Ciclodecanos
- Diterpenos
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Economia de saúde e organizações
- Compostos de platina
- Economia
- Pemetrexede
- Gemcitabina
- Paclitaxel
- Cisplatina
- Pembrolizumab
- Impostos
Outros números de identificação do estudo
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (Outro identificador: Merck Sharp & Dohme LLC)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .